Clinical Trials Logo

Rhinitis, Allergic, Perennial clinical trials

View clinical trials related to Rhinitis, Allergic, Perennial.

Filter by:

NCT ID: NCT01270256 Completed - Clinical trials for Perennial Allergic Rhinitis

NasoNeb Delivery of an Intranasal Steroid

Start date: January 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to see if a nasal steroid drug delivered to the nose with the NasoNeb™ inhaler improves the symptoms of people with perennial allergic rhinitis (year round allergy symptoms).

NCT ID: NCT01244217 Completed - Rhinitis Perennial Clinical Trials

Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)

Start date: October 2010
Phase: Phase 2/Phase 3
Study type: Interventional

Primary Objective: - To evaluate safety (4 weeks) Secondary Objectives: - To evaluate the long-term safety (12 weeks) - To evaluate the efficacy - To characterize the pharmacokinetic profile

NCT ID: NCT01231464 Completed - Clinical trials for Rhinitis, Allergic, Perennial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis

Start date: September 2009
Phase: Phase 3
Study type: Interventional

The objective of this study is to compare the efficacy and safety of Fluticasone Furoate Nasal Spray (FFNS), that is FFNS with placebo in Chinese adult and adolescent subjects with Allergic Rhinitis as AR. There are 3 phases, 2 to14 day run in, 2 week treatment, and 3 to 5 day follow up. After run in period, at least 360 subjects with AR ( ages of 12yrs and 65yrs, inclusive) will be randomised to receive FFNS 110ug once daily or placebo for 2 weeks. The primary endpoint is the change from baseline of reflective total nasal symptom score (rTNSS) during treatment period, and the secondary endpoints include mean change from baseline in nasal finding scores by rhinoscopy at completion of study treatment, and severity of overall inference in activities of daily living. Safety measures include AE (Adverse Event) reports, ECGs (Electrocardiograph), physical exams, vital signs, and nasal exam. In addition, reflective total ocular symptom score (rTOSS) will be measured as an explorative endpoint, only in the specific AR (Allergic Rhinitis) patients with severe ocular symptoms.

NCT ID: NCT01228630 Completed - Clinical trials for Perennial Allergic Rhinitis

Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.

Start date: August 2011
Phase: Phase 3
Study type: Interventional

The loratadine-pseudoephedrine combination has proven to be more effective than the use of these individual components. This prospective, randomized, double-blind and paralel study, in which patients with perennial allergic rhinitis receive one of loratadine + pseudoephedrine association drug for treatment of signs and symptoms during 4 weeks.

NCT ID: NCT01221285 Completed - Asthma Clinical Trials

Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium

Start date: September 2010
Phase: Phase 1
Study type: Interventional

This trial is a biomarker-based pilot study of the safety of Cockroach Subcutaneous Immunotherapy in Cockroach-sensitive Adults (SCITCO) who have a history of perennial allergic rhinitis, asthma, or both.

NCT ID: NCT01216384 Completed - Asthma Clinical Trials

Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers

Start date: October 2010
Phase: Phase 1
Study type: Interventional

The primary objective of the current study is to investigate the safety and tolerability of BI 671800 HEA in healthy Chinese male volunteers following single oral administration, and healthy Japanese male volunteers following single oral administration and multiple administrations.

NCT ID: NCT01199757 Completed - Clinical trials for Rhinitis, Allergic, Perennial

A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

Start date: July 10, 2009
Phase: N/A
Study type: Observational

Previous publications have indicated that Allergic Rhinitis (AR) patients suffering from both ocular and nasal symptoms have a greater burden of illness and lower quality of life than patients suffering from nasal symptoms alone. Fluticasone furoate (FF) acts against both nasal and ocular symptoms. The purpose of this study was to evaluate the differences in symptom control (both perceptually and objectively) and resource use for patients with current seasonal AR.

NCT ID: NCT01172613 Recruiting - Clinical trials for Rhinitis, Allergic, Seasonal

Optimal Concentration of Dermatophagoides Pteronyssinus (Dp) Allergen Extract for Skin Prick Test (SPT) of Thai Population

DSPT
Start date: June 2010
Phase: Phase 2/Phase 3
Study type: Observational

The purpose of this study is to determine the appropriate concentration of diagnostic reagent of house dust mite (Dp) to be used in diagnostic allergy skin prick test among Thai population with allergic rhinitis.

NCT ID: NCT01165424 Completed - Clinical trials for Rhinitis, Allergic, Perennial

A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)

Start date: April 2010
Phase: Phase 3
Study type: Interventional

Mometasone furoate nasal spray (MFNS) is a once-a-day product. This is a multi-center, open-label study of MFNS in children with perennial allergic rhinitis. MFNS will be administered to pediatric subjects (3-15 years old) with perennial allergic rhinitis at a dose of 100 to 200 μg/day (once daily) for 12 weeks. Subjects (subject's legal representatives) provided consent to continue treatment beyond 12 weeks will receive treatment for up to 24 weeks. At each clinic visit, observation of adverse events, nasal symptom scores, and nasal findings will be evaluated. The presence/absence of serious adverse events and trial procedure-related AEs will be reviewed 30 days after the end of the follow-up.

NCT ID: NCT01154153 Completed - Clinical trials for Rhinitis, Allergic, Perennial and/or Seasonal

Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

Start date: June 2010
Phase: Phase 4
Study type: Interventional

The primary objective was to evaluate the effect of a 6-week treatment with TAA-AQ (110 μg) and TAA-AQ (220 μg) once daily (QD) versus placebo on hypothalamic-pituitary-adrenal (HPA) axis function as measured by serum cortisol AUC(0-24 hr) in children (>=2 to <12 years old) with allergic rhinitis (AR).